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Abstract
Hyperhomocysteinemia (HHcy) is a risk factor for vascular disease, but the underlying
mechanisms remain incompletely defined. Reduced bioavailability of nitric oxide (NO) is a
principal manifestation of underlying endothelial dysfunction, which is an initial event in vascular
disease. Inhibition of cellular methylation reactions by S-adenosylhomocysteine (AdoHcy), which
accumulates during HHcy, has been suggested to contribute to vascular dysfunction. However,
thus far, the effect of intracellular AdoHcy accumulation on NO bioavailability has not yet been
fully substantiated by experimental evidence. The present study was carried out to evaluate
whether disturbances in cellular methylation status affect NO production by cultured human
endothelial cells. Here, we show that a hypomethylating environment, induced by the
accumulation of AdoHcy, impairs NO production. Consistent with this finding, we observed
decreased eNOS expression and activity, but, by contrast, enhanced NOS3 transcription. Taken
together, our data support the existence of regulatory post-transcriptional mechanisms modulated
by cellular methylation potential leading to impaired NO production by cultured human
endothelial cells. As such, our conclusions may have implications for the HHcy-mediated
reductions in NO bioavailability and endothelial dysfunction.
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Introduction
Hyperhomocysteinemia (HHcy) is a risk factor for vascular disease, but the underlying
mechanisms remain incompletely defined (Castro et al. 2006).
Cellular methylation potential is determined by the concentrations of the homocysteine
(Hcy) precursor, S-adenosylhomocysteine (AdoHcy). AdoHcy inhibits virtually all S-
adenosylmethionine (AdoMet)-dependent-methyltransferases, which, in turn, catalyse the
transfer of a methyl group from AdoMet to a wide variety of target molecules (including
DNA and proteins), forming AdoHcy and the methylated substrate (Handy et al. 2011).
AdoHcy is further converted into Hcy and adenosine by a reversible reaction catalysed by
AdoHcy hydrolase, which favours AdoHcy production. When Hcy accumulates, its
precursor, AdoHcy, will accumulate, as well. Elevated Hcy was shown to be directly
associated with increased extracellular and intracellular AdoHcy concentrations in vivo
(Castro et al. 2006). Increasing evidence indicates that Hcy may be regarded as a cellular
demethylating agent, at least at the DNA level. In fact, we and others have observed an
association between high levels of Hcy and AdoHcy, which, in turn, is correlated with
global DNA hypomethylation status (Castro et al. 2006). In addition, several studies support
the existence of epigenetic mechanisms in the context of Hcy-related endothelial
dysfunction (Handy et al. 2011).
Vascular disease begins with endothelial dysfunction, a sensitive indicator of the
atherosclerotic process, occurring even before the clinical manifestations of the pathology
and predicting adverse clinical outcomes (Tai et al. 2004; Weiss et al. 2002). Reduced
bioavailability of nitric oxide (NO) and consequent impairment of endothelium-dependent
vasodilation result in endothelial dysfunction. Nitric oxide is synthesized by endothelial
cells from the amino acid, L-arginine, via the enzymatic action of endothelial nitric oxide
synthase (eNOS) and is an important mediator of intracellular signalling and a potent anti-
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atherogenic molecule responsible for the maintenance of vascular homeostasis (Luksha et al.
2009). Endothelial NOS expression is subject to significant degrees of regulation from
transcriptional to post-translational levels (Tai et al. 2004; Weiss et al. 2002). Asymmetric
dimethylarginine (ADMA) is an endogenous competitive inhibitor of eNOS and is derived
from the proteolysis of methylated arginine residues in proteins (Cardounel et al. 2007).
Methylation of arginine in proteins is carried out by protein-arginine methyltransferases type
1 (PRMTs 1), transferring one methyl group from AdoMet to various proteins and forming,
in addition, AdoHcy (Boger 2006). AdoHcy is further hydrolysed to Hcy. Because of the
metabolic link between ADMA and Hcy, ADMA has been suggested as a potential mediator
of endothelial dysfunction in HHcy (Lentz et al. 2003; Dayal and Lentz 2005; Stuhlinger
and Stanger 2005; Boger 2006). Evidence from animal models and clinical studies have
suggested that accumulation of ADMA contributes to impaired NO generation and disease
pathogenesis (Teerlink et al. 2009).
Several in vivo studies, either in animal models (Dayal et al. 2001; Devlin et al. 2004;
Celotto et al. 2010) or in humans with severe (Celermajer et al. 1993), mild (Tawakol et al.
1997; Woo et al. 1997), or transient (Chambers et al. 1999; Chao et al. 2000) HHcy, showed
that endothelial dysfunction is a key vascular phenotype occurring in the setting of HHcy;
however, the mechanistic understanding of the association between HHcy and impaired NO
bioavailability remains to be completely defined. The present study was designed to evaluate
whether a hypomethylating environment, induced by accumulation of the Hcy precursor,
AdoHcy, perturbs NO production by cultured human endothelial cells.
Materials and methods
Cell culture
Human umbilical vein endothelial cells (HUVEC) were obtained from umbilical cords of
healthy foetuses from uncomplicated pregnancies and vaginal deliveries from healthy
mothers, as described (Castro et al. 2005), or commercially obtained from Lonza
(Walkersville, MD, USA). The cord was collected in buffered solution [4 mmol/L KCl, 140
mmol/L NaCl, 11 mmol/L D-glucose (all from Merck, Darmstadt, Germany), 10 mmol/L
HEPES (Gibco, Grand Island, NY, USA), and 1% antibiotic–antimycotic solution (Sigma,
St. Louis, MO, USA)], and stored at −4°C. Within 4 days, cells were isolated by collagenase
(Gibco, Grand Island, NY, USA) treatment and were cultured essentially as previously
described (Castro et al. 2005). Cells were grown in coated six-well plates (6 × 10 cm2), 75
cm2 flasks, or 100 cm2 disks depending on subsequent analysis.
All experiments were performed at 80% confluence and between the fourth and sixth
passage. After the removal of the culture medium, fresh medium, either without (control) or
with increasing concentrations of an AdoHcy hydrolase inhibitor (adenosine dialdehyde,
ADA) (5, 10, and 20 μmol/L) was added. After 24 h of incubation, lactate dehydrogenase
(LDH) release was evaluated in the cell culture medium using the Cytotoxicity Detection Kit
(Roche Diagnostic GmbH, Mannheim, Germany).
Metabolite analysis
Aliquots of the medium were collected from cells grown in six-well plates after 24 h of
incubation and stored at −20°C for further Hcy and ADMA analysis. HUVEC were then
extensively washed with ice-cold phosphate-buffered saline (PBS) and exposed to
denaturation buffer for 15 min at 4°C. Denaturation buffer consisted of 1.5 mmol/L MgCl2,
10 mmol/L KCl, 1 mmol/L DTT (all from Merck, Darmstadt, Germany), 10 mmol/L HEPES
(Gibco, Grand Island, NY, USA), and 1.0 mmol/L PMSF (Sigma, St Louis, MO, USA) (pH
7.9), containing 1% (v/v) Triton X-100 (from Merck, Darmstadt, Germany). The cell lysate
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was centrifuged at 4°C, 1,200 rpm, for 10 min. The supernatant (cytosol) was collected, and
two aliquots were taken. One was promptly deproteinized with an equal volume of 10%
perchloric acid and stored at −20°C for further AdoMet and AdoHcy evaluation, and the
remainder was immediately frozen and kept at −20°C until protein determination.
Extracellular total Hcy (tHcy) levels, defined as the total concentration of Hcy after
reductive cleavage of all disulfide bonds, were determined by HPLC analysis according to
Araki and Sako (1987), with minor modifications. Extracellular ADMA concentrations were
measured by HPLC with fluorescence detection as described previously (Teerlink et al.
2002), using modified chromatographic separation conditions (de Jong and Teerlink 2006).
Intracellular AdoHcy and AdoMet concentrations were analysed by LC–MS/MS (Struys et
al. 2000).
NO levels
Nitric oxide production in response to intracellular Ado-Hcy accumulation was measured by
the Griess reaction (Guevara et al. 1998). For this purpose, cells were grown in six-well
plates. Culture medium was replaced 24 h before incubations, which were conducted in 0.8
mL of basal endothelial cell culture medium without phenol red. After 12 and 24 h of
incubation, aliquots of culture medium were collected for NOx quantification. In addition,
incubations for 18 h with 1 mmol/L of L-NG-nitroarginine (L-NNA, from Cayman
Chemicals, Ann Arbor, MI, USA), an eNOS inhibitor, in the presence and in the absence of
20 μmol/L of ADA, were also performed. Freshly collected (200 μL) cell culture
supernatants were mixed with 200 μL Griess reagent (1:1 mixture of 1% sulphanilamide in
5% H3PO4 and 0.1% naphthylethylenediamine dihydrochloride in water) and incubated in
96-well plates for 10 min at room temperature. Absorbance at 543 nm was recorded. Cells
were lysed and protein concentrations were determined. Nitrite concentration was calculated
using sodium nitrite standards and normalized by cellular protein concentration (μmoles of
NO2−/mg of cell protein).
Western blotting
Western blot was performed for analysis of eNOS levels, using four independent cultures.
30 cm2 of 80% confluent HUVEC was used for each sample. Cells were washed three times
with ice-cold PBS, directly lysed in cell lysis buffer containing protease inhibitors (Sigma,
St Louis, MO, USA), collected with a cell scraper, and sonicated. After centrifugation, the
obtained supernatant was used for total protein determination and Western blot analysis.
Protein concentrations were quantified using the DC Protein Assay (Biorad, Hercules, CA,
USA).
Protein samples (20–30 μg) were separated on 10% SDS-polyacrylamide gels and
transferred onto nitrocellulose membranes (Hybond ECLTM, Amersham, GE Healthcare,
Chalfont St. Giles, UK). The membranes were incubated with anti-eNOS (at a 1:500
dilution; Cell Signalling, Danvers, MA, USA) and anti-β-actin (at a 1:2000 dilution; Sigma,
St. Louis, MO, USA) antibodies. A secondary anti-rabbit IgG HRP secondary antibody (Cell
Signaling, Danvers, MA, USA) at a 1:2,000 dilution was used. Primary antibody incubation
was performed overnight at 4°C, and secondary antibody incubation was performed for 1–
1.5 h at room temperature. An ECL Plus Western Blotting Detection System was used for
protein detection (GE Healthcare, Chalfont St. Giles, UK), membranes were exposed to
Amersham Hyperfilm HCl (GE Healthcare, Chalfont St. Giles, UK), and a VersaDoc
scanning system (BioRad, Hercules, CA, USA) was used for densitometric analysis.
Barroso et al. Page 4
Amino Acids. Author manuscript; available in PMC 2013 March 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
eNOS activity
eNOS activity was determined by measuring the efficacy of conversion of [3H]-Arg to [3H]-
Citrulline in protein extracts from cultured cells using a commercial kit (Cayman Chemicals,
Ann Arbor, MI, USA), according to the manufacturer’s instructions. Four independent
cultures were used.
Briefly, cells were grown to confluence in 100 cm2 disks, treated with 20 μmol/L of ADA
for 24 h, washed with PBS, harvested in PBS containing 1 mmol/L of EDTA, and
centrifuged. The obtained pellet was lysed in 100 μL of lysis buffer, centrifuged, and 10 μL
of the obtained supernatant were incubated with 40 μL of reaction buffer containing [3H]-
Arg for 60 min at 37°C. Reactions were terminated by addition of 400 μL of Stop Buffer
from the kit. Cell lysates were applied to a cation exchange resin column from the kit. The
citrulline was eluted, radioactivity determined, and normalized via protein concentration.
Reverse transcription and quantitative PCR
Total RNA was extracted from three independent cultures using the RNeasy Minikit
(Qiagen, Valencia, CA, USA) and was reverse transcribed (2 μg) into cDNA using
oligo(dT) SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Specific
primers for NOS3 gene (NM_000603.3) F:5′-CGTCCCTGTGGAAAGACAAG-3′ and R:
5′-CACGATGGTGACTTTGGCTA-3′ were designed with the Universal Probe Library
Assay Design Center (Roche Applied Science). EIF4A2 gene (NM_001967.3) served as an
internal control gene with F:5′-GTGTGAACT GGACCCTGTTG-3′ and R:5′-
TATTTAACATTCAAACT TCATTAAGACATG-3′ primers. Amplification reaction
assays were performed in triplicate and contained 1× SYBR Green PCR Mastermix
(Applied Biosystems, Foster City, CA, USA) and primers at optimal concentration. A hot
start at 50°C for 2 min was followed by an extension period at 95°C for 10 min and then for
40 cycles at 95°C for 15 s and 60°C for 1 min, using the 7300 Real Time PCR System
(Applied Biosystems, Foster City, CA, USA). Fluorescence emission was detected for each
PCR cycle and the Ct (threshold cycle) values were determined.
Statistics
Data are presented as means ± SD. Statistical evaluation of the data was performed by
paired Student’s t test for comparisons between two groups, and by one-way analysis of
variance followed by Dunnett’s test for comparisons between more than two groups. A
value of p <0.05 was regarded as significant.
Results
Intracellular AdoHcy and AdoMet levels
As shown in Fig. 1a, ADA was effective in promoting a significant AdoHcy intracellular
accumulation, confirming its inhibitory effect on AdoHcy hydrolase. AdoMet levels
remained unaltered (189 ± 50, 216 ± 22, 169 ± 50 and 203 ± 30 pmol/mg protein for ADA
0, 5, 10, and 20 μmol/L, respectively, p = NS for trend). A significant (p <0.01 vs. control)
decrease in intracellular AdoMet/AdoHcy ratio was observed (5.8 ± 1.6, 1.8 ± 0.2, 1.0 ± 0.3
and 0.8 ± 0.1 for ADA 0, 5, 10, and 20 μmol/L, respectively), which was exclusively
defined by the increasing levels of AdoHcy.
Hcy and ADMA export, the effect of AdoHcy hydrolase inhibition
In the presence of increasing concentrations of ADA, there was a significant decrease in
both tHcy and ADMA extracellular concentrations, showing that both export levels were
reduced in an ADA dose-dependent manner (Fig. 1b, c).
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Lactate dehydrogenase
Cell LDH release (%, average ± SD, n = 3), an indicator of cytotoxicity, after 24 h of
incubation, in the absence (control 100 ± 8) or presence of the tested ADA concentrations
(111 ± 16; 110 ± 17 and 105 ± 12, for ADA = 5, 10 or 20 μmol/L, respectively) was similar.
Therefore, a possible cytotoxic effect for the ADA was ruled out in the present study.
NO levels under intracellular AdoHcy accumulation
We measured nitrite, a metabolite of NO, as an index of endothelial NO production. We
observed a decrease in extracellular nitrite concentrations, after 12 and 24 h of incubation,
which, for the highest ADA concentration tested, reached statistical significance (Fig. 2).
The observed difference of extracellular nitrite concentrations, observed in the absence and
the presence of 20 μmol/L of ADA, was abolished by co-incubation with 1 mmol/L of L-
NNA, an eNOS inhibitor (Fig. 3).
eNOS: transcriptional and translational levels and enzymatic activity under intracellular
AdoHcy accumulation
eNOS protein and activity—The expression of eNOS protein was studied using Western
blot analysis. A typical band with a molecular mass of approximately 140 kDa was detected
with an anti-eNOS antibody, with β-actin used as reference. Relative expression of eNOS
was significantly reduced by intracellular AdoHcy accumulation (Fig. 4a1).
The functionality of the eNOS protein was assessed by monitoring the efficacy of L-arginine
to L-citrulline conversion in cell lysates. Compared with controls, cells incubated with 20
μmol/L ADA for 24 h showed a significant decrease in eNOS activity (p <0.05) (Fig. 4a2).
NOS3 mRNA—NOS3 mRNA levels were quantified by RT-qPCR. As opposed to the
ADA-induced decrease of eNOS protein and activity, a significant increase of NOS3 gene
transcription was found directly related to the intracellular accumulation of AdoHcy (Fig.
4b).
Discussion
The major finding of the present study is that intracellular accumulation of AdoHcy resulted
in impaired NO production by cultured human endothelial cells. Furthermore, decreased
eNOS protein expression and corresponding enzymatic activity were observed, but increased
NOS3 mRNA levels were found.
Hcy metabolism is biochemically linked to the principal epigenetic tag (5-methylcytosine)
found in DNA (Handy et al. 2011). Inhibition of cellular methylation reactions by AdoHcy,
which accumulates in the setting of HHcy, has been suggested to contribute to vascular
dysfunction. Accordingly, several studies support the existence of epigenetic mechanisms in
the context of Hcy-related endothelial dysfunction (Handy et al. 2011). However, thus far,
the effect of intracellular AdoHcy accumulation on NO bioavailability has not yet been fully
examined. The present study was designed to evaluate whether a hypomethylating
environment, caused by intracellular AdoHcy accumulation, contributes to the impairment
of endothelium-dependent NO production in cultured human endothelial cells.
Because AdoHcy hardly crosses the cell membrane (Ueland 1982; Castro et al. 2005), the
intracellular accumulation of the Hcy precursor, AdoHcy, was achieved through the
pharmacological inhibition of AdoHcy hydrolase by an adenosine analogue, ADA. As
shown in Fig. 1, increasing concentrations of ADA were effective in increasing intracellular
AdoHcy levels. Supporting our previous observations, the levels of AdoHcy exclusively
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determined the decrease in AdoMet/AdoHcy ratio since AdoMet levels remained constant
over the range of ADA concentrations used (Castro et al. 2005). Hcy export from the
HUVEC reflects an imbalance between its intracellular production and metabolism.
Therefore, and as expected, a decrease in the concentration of extracellular Hcy was
observed (Fig. 1b), confirming the inhibitory effect of ADA upon AdoHcy hydrolase.
The rapid metabolism and short half-life of NO brings additional difficulties to its analytical
assessment (Guevara et al. 1998). However, the measurement of nitrite, a metabolite of NO,
is currently used as an index of endothelial NO production (Guevara et al. 1998). As shown
in Fig. 2, with increasing concentrations of ADA, a dose-dependent decrease in extracellular
nitrite levels was observed in our system. This effect was abolished in the presence of the
eNOS inhibitor, the L-NNA (Fig. 3). This finding confirmed that the decreased nitrite
formation caused by intracellular AdoHcy accumulation was due to impaired NO synthesis
by eNOS. Previous studies also found that NO release from cultured endothelial cells was
impaired in the presence of elevated Hcy (Upchurch et al. 1997). In addition, in HHcy mice
with endothelial dysfunction, elevated AdoHcy and decreased AdoMet/AdoHcy ratio were
observed (Dayal et al. 2001). ADMA is an endogenous and potent inhibitor of eNOS that
was found to accumulate in different study models including in humans with HHcy and
vascular disease (Teerlink et al. 2009). Consequently, the accumulation of ADMA was
suggested to contribute to reduced NO generation in Hcy-dependent endothelial dysfunction
(Teerlink et al. 2009). Our results suggest that the accumulation of the Hcy precursor, Ado-
Hcy, is not responsible for the ADMA accumulation observed in the setting of HHcy. In
fact, an AdoHcy intracellular accumulation (Fig. 1a) was associated with decreased
extracellular ADMA levels (Fig. 1c) in our cellular model. In addition, a significant
impaired NO production was observed (Figs. 2, 3, 4). Therefore, our results suggest the
existence of an ADMA-independent mechanism triggered by AdoHcy accumulation that
may contribute to the HHcy-related impaired NO bioavailability. Interestingly, it has been
recently suggested that the increase in ADMA levels, seen in humans with HHcy and
vascular disease, is probably due to the decline of renal function and is not directly related to
HHcy-dependent metabolic changes, nor does it contribute to endothelial dysfunction
(Wilcken et al. 2006; van Guldener et al. 2007).
Nitric oxide is generated in endothelial cells from conversion of L-arginine to L-citrulline by
the enzymatic action of eNOS, which in turn is encoded by the NOS3 gene. To investigate
whether the observed impairment in endothelial NO bioavailability was caused by decreased
eNOS expression, we focused on its translational and transcriptional expression. As shown
in Fig. 4a1, decreased eNOS protein levels were observed, suggesting eNOS down-
regulation by intracellular AdoHcy accumulation. In agreement with these observations, an
Hcy-induced decrease in eNOS protein levels was seen using human aortic endothelial cells
in a prior study (Jiang et al. 2005).
We also examined the functionality of eNOS protein, monitoring the efficacy of L-arginine
to L-citrulline conversion by cell lysates. Compared with controls, cells incubated with 20
μmol/L of ADA for 24 h showed a significant decrease in eNOS activity (Fig. 4a2), which is
consistent with our findings of decreased nitrite levels (Fig. 2) and decreased eNOS levels
(Fig. 4a1). Previous reports concerning Hcy-induced disturbances in eNOS activity are
controversial. In fact, no effect (Heydrick et al. 2004) or down-regulation (Dayal et al. 2008)
by Hcy upon eNOS activity had been reported previously in cultured endothelial cells.
Surprisingly, we found that relative NOS3 mRNA levels were significantly increased by
intracellular AdoHcy accumulation (Fig. 4b). We, and others, have already shown that
global DNA hypomethylation is induced by AdoHcy accumulation (Castro et al. 2005,
2006). It is well known that DNA methylation is an epigenetic mechanism of gene
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regulation and that decreased methylation patterns usually are related to increased
transcription of target genes by several mechanisms (Handy et al. 2011). However, it has
been previously shown that in eNOS-expressing cells the core promoter CpG dinucleotides
are fully demethylated (Chan et al. 2004). Accordingly, it was reported that treatment of
human endothelial cells with a DNA methyltransferase inhibitor did not alter the levels of
NOS3 mRNA, as it did in eNOS non-expressing cells (Chan et al. 2004). These observations
led us to exclude DNA hypomethylation as causing the increase in NOS3 mRNA levels
observed in our model. However, DNA is not the only target for the AdoHcy-mediated
inhibition of AdoMet-dependent methyltransferases, and multiple targets may be affected,
including proteins implicated in eNOS expression in human endothelial cells. An example of
this point is the forkhead box O 1 (FOXO1) transcription factor, which acts as
transcriptional repressor of NOS3 expression. Recent data showed that protein arginine
methyltransferase 1 (PRMT1) methylates FOXO1, which in turn hinders its phosphorylation
and export to cytoplasm, thus augmenting the expression of FOXO1 target genes (Yamagata
et al. 2008). The same authors showed that, in a HUVEC model, the knockdown of PRMT1
induced NOS3 expression (Yamagata et al. 2008). Moreover, our data show that
intracellular AdoHcy accumulation was associated with decreased extracellular ADMA
concentrations, as well as increased relative NOS3 mRNA levels. Recent observations by
our group showed that protein-incorporated ADMA is strongly decreased by AdoHcy
intracellular accumulation in HUVEC (Esse et al. 2010), indicating that PRMT1 is a target
for AdoHcy-mediated inhibition and suggesting that FOXO1-methylation may be
subsequently reduced by AdoHcy. Taken together, these findings suggest that PRMT1 was
subjected to AdoHcy-mediated inhibition, causing FOXO1 hypomethylation and the
observed Ado-Hcy-dependent enhanced NOS3 transcription (Fig. 4b).
Regulation of eNOS protein levels is a complex process that is mediated at several levels,
including post-transcriptionally (Fish and Marsden 2006). In fact, our paradoxical
observations concerning eNOS transcriptional and translational levels disclose the existence
of post-transcriptional events to be ascertained. Similar observations have been reported in
different contexts. For example, in livers from patients with alcoholic hepatitis, NOS3
mRNA was found to be increased, but eNOS activity decreased despite no differences in
eNOS protein expression compared with non-alcoholic livers (Mookerjee et al. 2007). In
addition, exercise training of diabetic animals was shown to lead to an increase in left
ventricular eNOS protein and a concomitant decrease in NOS3 mRNA (Grijalva et al. 2008).
In conclusion, we observed that a hypomethylating environment, due to increased
intracellular levels of AdoHcy, impairs NO production by cultured human endothelial cells.
This finding may have implications in the HHcy-mediated reduction in NO bioavailability
and endothelial dysfunction. Taken together, our results clearly suggest that post-
transcriptional events may be crucial mechanisms in the regulation of NO synthesis, and
their modulation by the cellular methylation potential demands further investigation.
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Fig. 1.
Intracellular AdoHcy (a), and extracellular Hcy (b) and ADMA (c) concentrations in
HUVEC incubated in culture medium supplemented with increasing concentrations of ADA
for 24 h. Data are presented as means ± SD. (**p <0.01 vs. control, n ≥ 3; *p <0.05 vs.
control, n = 6)
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Fig. 2.
Nitrite levels in HUVEC culture medium measured by the Griess reaction. HUVEC were
incubated in culture medium supplemented with increasing concentrations of ADA for 12 or
24 h. Data are presented as means ± SD, and are representative of three different cell lines
(*p <0.05 vs. control)
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Fig. 3.
Nitrite levels in HUVEC culture medium supplemented with 0 and 20 μmol/L
concentrations of ADA in the absence and in the presence of L-NNA (1 mmol/L) after 18 h
of incubation. Data are presented as means ± SD (*p <0.05 vs. control, n = 3)
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Fig. 4.
eNOS expression in HUVEC cultured with increasing concentrations of ADA after 24 h of
incubation. Data are means ± SD. a1 relative eNOS expression was determined by Western
blotting with antibodies against eNOS and β-actin. Densitometry was performed on four
blots. A representative blot is shown. (*p <0.05 vs. control). a2 eNOS activity was measured
in HUVEC incubated in the absence or presence of 20 μmol/L of ADA after 24 h by
measuring the conversion of L-arginine to L-citrulline in cell lysates. Four different
experiments were performed each in duplicate. (*p <0.05 paired Student’s t test vs. control).
b Real-time quantitative RT-PCR of relative NOS3 mRNA levels of three or more
independently prepared cDNA pools representing independent RNA isolations. (*p <0.05
vs. control)
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